Skip to content

A Clinical Study on the Efficacy and Safety of Qihuang Jianpi Zishen Granules in the Treatment of SLE

A Clinical Study on the Efficacy and Safety of Qihuang Jianpi Zishen Granules in the Treatment of SLE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000173
Enrollment
Unknown
Registered
2026-01-24
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Interventions

Observation group:On the basis of conventional treatment, Qihuang Jianpi Zishen granule was added. The conventional treatment included prednisone 0.5-1.0 mg/kg·d, hydroxychloroquine sulfate 0.2 g twic
Control Group:Prednisone 0.5-1.0 mg/kg·d, hydroxychloroquine sulfate 0.2 g twice daily, mycophenolate mofetil capsule 0.5 g twice daily

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Based on the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus (SLE); (2) Patients diagnosed with spleen-kidney deficiency syndrome according to traditional Chinese medicine (TCM) differentiation; (3) Age =18 years and =65 years; (4) SLEDAI-2000 score between 5 and 9 points (5 points = SLEDAI-2000 = 9 points); (5) Participants who have signed an informed consent form and voluntarily agree to participate.

Exclusion criteria

Exclusion criteria: (1) Individuals with allergies to the investigational drug; (2) Individuals with fundus and visual field abnormalities or arrhythmias; (3) Individuals with other rheumatic or immunological diseases; (4) Individuals with severe infections; (5) Individuals with a positive Coombs test; (6) Individuals who have used biologics or immunosuppressants within the past 12 weeks (excluding hydroxychloroquine sulfate); (7) Individuals who are pregnant, breastfeeding, or have mental illnesses.

Design outcomes

Primary

MeasureTime frame
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score;C3;C4;ANA;ds DNA;IgA;IgG;IgM;Blood Routine;24hPRO;Scr;eGFR;ACR;TPCR;Urine protein series;Interleukin-6 (IL-6);Interleukin-10 (IL-10);Tumor Necrosis Factor-alpha (TNF-a);Interferon-gamma (IFN-?);Toll-like receptor 4 (TLR4);Nuclear Factor kappa-B p65 (NF-?B p65);Beclin-1;Sequestosome-1 (p62);Nephrin;

Secondary

MeasureTime frame
Quality of Life Assessment;Depression Self-Rating Scale;Anxiety Self-Rating Scale;

Countries

China

Contacts

Public ContactLi Ming

The First Affiliated Hospital of Anhui University of Chinese Medicine

2868283961@qq.com18455137261

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026